Streetbeat News

QSI

Quantum-Si incorporated

Industry

Biotechnology

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

Open

1.74

Mkt cap

245M

Volume

11M

High

1.78

P/E Ratio

-2.69

52-wk high

2.58

Low

1.64

Div yield

N/A

52-wk low

0.61

Quantum-Si Incorporated (QSI) is highlighted as a potential top momentum stock pick. The article explores whether QSI has the characteristics that make it appealing to momentum investors.

Portfolio Pulse from

December 11, 2024 | 6:15 pm

Quantum-Si Incorporated held its Q3 2024 earnings call, discussing financial performance and company updates.

Portfolio Pulse from

November 12, 2024 | 11:00 pm

Quantum-Si Incorporated (QSI) reported a Q3 loss of $0.18 per share, which was better than the Zacks Consensus Estimate of a $0.21 loss. However, this is a larger loss compared to $0.15 per share a year ago.

Portfolio Pulse from

November 12, 2024 | 3:00 pm

In Monday's after-market session, several health care stocks experienced significant price movements. iRhythm Technologies (IRTC) saw a notable increase of 16.6%, while Sensei Biotherapeutics (SNSE) faced a sharp decline of 20.5%. Medpace Holdings (MEDP) also dropped by 12.17% following their Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 21, 2024 | 8:31 pm

In Monday's after-market session, several health care stocks experienced significant price movements. Repare Therapeutics, Cognition Therapeutics, and Singular Genomics Sys were among the top gainers, while IGM Biosciences and Karyopharm Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 8:31 pm

Quantum-Si has announced that Liberate Bio has integrated their Platinum Next-generation Protein Sequencer into its platform. This integration aims to enhance the development of novel gene therapies with improved targeting capabilities.